135 related articles for article (PubMed ID: 38182719)
1. Comparison of mortality rates in patients with carbapenem-resistant Enterobacterales bacteremia according to carbapenemase production: a multicenter propensity-score matched study.
Baek MS; Kim JH; Park JH; Kim TW; Jung HI; Kwon YS
Sci Rep; 2024 Jan; 14(1):597. PubMed ID: 38182719
[TBL] [Abstract][Full Text] [Related]
2. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
[TBL] [Abstract][Full Text] [Related]
3. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
Wu AY; Chang H; Wang NY; Sun FJ; Liu CP
J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.
Hassoun-Kheir N; Hussein K; Karram M; Saffuri M; Badaan S; Peleg S; de Kraker MEA; Aboelhega W; Warman S; Alon T; Eluk O; Geffen Y; Paul M
Clin Microbiol Infect; 2023 May; 29(5):629-634. PubMed ID: 36641053
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.
Debnath A; Pillinger KE; Martin AJ; Dobrzynski D; Cameron A; Shulder S
Ann Pharmacother; 2023 Jul; 57(7):803-812. PubMed ID: 36268974
[TBL] [Abstract][Full Text] [Related]
7. Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing
Park JJ; Jung EJ; Kim JY; Seo YB; Lee J; Jung Y
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0028722. PubMed ID: 35708330
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of carbapenem-resistant Enterobacterales bacteremia in pediatric patients.
Liu YC; Lu CY; Yen TY; Chang LY; Chen JM; Lee PI; Huang LM
J Microbiol Immunol Infect; 2023 Feb; 56(1):84-92. PubMed ID: 36376217
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
[TBL] [Abstract][Full Text] [Related]
10. Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant
Lim FK; Liew YX; Cai Y; Lee W; Teo JQM; Lay WQ; Chung J; Kwa ALH
Front Cell Infect Microbiol; 2020; 10():579462. PubMed ID: 33178629
[No Abstract] [Full Text] [Related]
11. Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort.
Rigatto MH; Ramos F; Barros A; Pedroso S; Guasso I; Gonçalves L; Bergo P; Zavascki AP
J Antimicrob Chemother; 2022 Oct; 77(11):3118-3125. PubMed ID: 36048569
[TBL] [Abstract][Full Text] [Related]
12. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
13. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
14. Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016-2018.
Paveenkittiporn W; Lyman M; Biedron C; Chea N; Bunthi C; Kolwaite A; Janejai N
Antimicrob Resist Infect Control; 2021 Jun; 10(1):88. PubMed ID: 34090537
[TBL] [Abstract][Full Text] [Related]
15. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA).
Paniagua-García M; Bravo-Ferrer JM; Pérez-Galera S; Kostyanev T; de Kraker MEA; Feifel J; Palacios-Baena ZR; Schotsman J; Cantón R; Daikos GL; Carevic B; Dragovac G; Tan LK; Raka L; Hristea A; Viale P; Akova M; Cano Á; Reguera JM; Bartoloni A; Florescu SA; Benea S; Bukarica L; Asensio Á; Korten V; Grundmann H; Goossens H; Bonten MJ; Gutiérrez-Gutiérrez B; Rodríguez-Baño J;
Clin Microbiol Infect; 2024 Feb; 30(2):223-230. PubMed ID: 38267096
[TBL] [Abstract][Full Text] [Related]
16. Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia.
Alraddadi BM; Heaphy ELG; Aljishi Y; Ahmed W; Eljaaly K; Al-Turkistani HH; Alshukairi AN; Qutub MO; Alodini K; Alosaimi R; Hassan W; Attalah D; Alswaiel R; Saeedi MF; Al-Hamzi MA; Hefni LK; Almaghrabi RS; Anani M; Althaqafi A
BMC Infect Dis; 2022 Jun; 22(1):542. PubMed ID: 35698046
[TBL] [Abstract][Full Text] [Related]
17. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
18. CP-CRE/non-CP-CRE Stratification And CRE Resistance Mechanism Determination Help In Better Managing CRE Bacteremia Using Ceftazidime-Avibactam And Aztreonam-Avibactam.
Zou H; Xiong SJ; Lin QX; Wu ML; Niu SQ; Huang SF
Infect Drug Resist; 2019; 12():3017-3027. PubMed ID: 31576152
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Carbapenem-Resistant
Rebold N; Lagnf AM; Alosaimy S; Holger DJ; Witucki P; Mannino A; Dierker M; Lucas K; Kunz Coyne AJ; El Ghali A; Caniff KE; Veve MP; Rybak MJ
Microbiol Spectr; 2023 Feb; 11(1):e0264722. PubMed ID: 36622246
[TBL] [Abstract][Full Text] [Related]
20. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.
Dequidt T; Bastian S; Nacher M; Breurec S; Carles M; Thiery G; Camous L; Tressieres B; Valette M; Pommier JD
Crit Care; 2023 Nov; 27(1):418. PubMed ID: 37915017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
